Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother (Q34518606)
Jump to navigation
Jump to search
scientific article
- Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual ( / ) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A do
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother |
scientific article |
|
Statements
1 reference
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother (English)
1 reference
Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual ( / ) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A do (English)
0 references
Ralph A DeFronzo
1 reference
David M Kendall
1 reference
Cindy J Rubin
1 reference
Pharis Mohideen
1 reference
Jean-Marie Ledeine
1 reference
Rene Belder
1 reference
Jorge Gross
1 reference
Paul Norwood
1 reference
Michael O'Mahony
1 reference
Kenneth Sall
1 reference
Greg Sloan
1 reference
Anthony Roberts
1 reference
Fred T Fiedorek
1 reference
1 reference
Identifiers
1 reference